rII Mutations Research Articles

Double-strand break repair and genetic recombination in topoisomerase and primase mutants of bacteriophage T4.

The effects of primase and topoisomerase II deficiency on the double-strand break (DSB) repair and genetic recombination in bacteriophage T4 were studied in vivo using focused recombination. Site-specific DSBs were induced by SegC endonuclease in the rIIB gene of one of the parents. The frequency/distance relationship was determined in crosses of the wild-type phage, topoisomerase II mutant amN116 (gene 39), and primase mutant E219 (gene 61). Ordinary two-factor (i×j) and three-factor (i k×j) crosses between point rII mutations were also performed. These data provide information about the frequency and distance distribution of the single-exchange (splice) and double-exchange (patch) events. In two-factor crosses ets1×i, the topoisomerase and primase mutants had similar recombinant frequencies in crosses at ets1-i distances longer than 1000 bp, comprising about 80% of the corresponding wild-type values. They, however, differ remarkably in crosses at shorter distances. In the primase mutant, the recombinant frequencies are similar to those in the wild-type crosses at distances less than 100 bp, being a bit diminished at longer distances. In two-factor crosses ets1×i of the topoisomerase mutant, the recombinant frequencies were reduced ten-fold at the shortest distances. In three-factor crosses a6 ets1×i, where we measure patch-related recombination, the primase mutant was quite proficient across the entire range of distances. The topoisomerase mutant crosses demonstrated virtually complete absence of rII(+) recombinants at distances up to 33 bp, with the frequencies increasing steadily at longer distances. The data were interpreted as follows. The primase mutant is fully recombination-proficient. An obvious difference from the wild-type state is some shortage of EndoVII function leading to prolonged existence of HJs and thus stretched out ds-branch migration. This is also true for the topoisomerase mutant. However, the latter is deficient in the ss-branch migration step of the DSB repair pathway and partially deficient in HJ initiation. In apparent contradiction to their effects on the DSB-induced site-specific recombination, the topoisomerase and primase mutants demonstrated about 3-8-fold increase in the recombinant frequencies in the ordinary crosses, with the recombination running exclusively via patches. This implies that most of the spontaneous recombination events are not initiated by dsDNA ends in these mutants.

Mismatch repair in recombination of bacteriophage T4.

Abstract The review focuses on the mechanism of mismatch repair in bacteriophage T4. It was first observed in T4 as an extra recombination mechanism, which contributed to the general recombination only when particular rII mutations were used as genetic markers (high-recombination markers), whereas it was inactive toward other rII mutations (low-recombination markers). This marker-dependent recombination pathway was identified as a repair of mismatches in recombinational heteroduplexes. Comparison of the structure of markers enabled us to make several specific conclusions on the nature of the marker discrimination by the mismatch repair system operating during T4 crosses. First, heteroduplexes with one mismatched base pair (either of transition or of transversion type) as well as single-nucleotide mismatches of indel type are not efficiently repaired. Second, among the repairable mismatches, those with two or more contiguous mismatched nucleotides are the most effectively repaired, whereas insertion of one correct pair between two mismatched ones reduces the repairability. Third, heteroduplexes containing insertion mutations are repaired asymmetrically, the longer strand being preferentially removed. Fourth, the sequence environment is an important factor. Inspection of the sequences flanking mismatches shows that runs of A:T pairs directly neighboring the mismatches greatly promote repair. The mismatch is recognized by T4 endonuclease VII and nicked on the 3' side. The nonpaired 3' terminus is attacked by the proofreading 3'→5' exonuclease of T4 DNA polymerase that removes the mismatched nucleotides along with several (~25) complementary nucleotides (the repair tract) and then switches to polymerization. The residual nick is ligated by DNA ligase (gp30). Most probably, the T4 system repairs replication and other mismatches as well; however, it might not discriminate old and new DNA strands and so does not seem to be aimed at repair of replication errors, in contrast to the most commonly studied examples of mismatch repair.

On the mutagenicity of homologous recombination and double-strand break repair in bacteriophage

The double-strand break (DSB) repair via homologous recombination is generally construed as a high-fidelity process. However, some molecular genetic observations show that the recombination and the recombinational DSB repair may be mutagenic and even highly mutagenic. Here we developed an effective and precise method for studying the fidelity of DSB repair in vivo by combining DSBs produced site-specifically by the SegC endonuclease with the famous advantages of the recombination analysis of bacteriophage T4 rII mutants. The method is based on the comparison of the rate of reversion of rII mutation in the presence and in the absence of a DSB repair event initiated in the proximity of the mutation. We observed that DSB repair may moderately (up to 6-fold) increase the apparent reversion frequency, the effect of being dependent on the mutation structure. We also studied the effect of the T4 recombinase deficiency (amber mutation in the uvsX gene) on the fidelity of DSB repair. We observed that DSBs are still repaired via homologous recombination in the uvsX mutants, and the apparent fidelity of this repair is higher than that seen in the wild-type background. The mutator effect of the DSB repair may look unexpected given that most of the normal DNA synthesis in bacteriophage T4 is performed via a recombination-dependent replication (RDR) pathway, which is thought to be indistinguishable from DSB repair. There are three possible explanations for the observed mutagenicity of DSB repair: (1) the origin-dependent (early) DNA replication may be more accurate than the RDR; (2) the step of replication initiation may be more mutagenic than the process of elongation; and (3) the apparent mutagenicity may just reflect some non-randomness in the pool of replicating DNA, i.e., preferential replication of the sequences already involved in replication. We discuss the DSB repair pathway in the absence of UvsX recombinase.

Abstract 1494: Characterization of a novel pro-tumorigenic TGF-β RII mutation from oral squamous cell carcinoma

Abstract TGF-β signaling plays various roles in tumor progression. Tumor suppressive TGF- β signaling is involved in early steps of carcinogenesis through loss of function which leads to deregulated proliferation. On the contrary, TGF- β signaling could be pro-tumorigenic in later stages of carcinogenesis by promoting epithelial-mesenchymal transition (EMT). Most of the reported TGF- β receptor-II mutations were loss of tumor suppressor function mutations and no pro-tumorigenic TGF- β receptor-II mutation has been identified in human tumors. This study aimed to analyze a novel mutation of TGF- β receptor-II found in metastatic lymph node of oral squamous cell carcinoma. This mutant converts amino acid 227 from I to T and amino acid 236 from N to D of TGF- β receptor-II. Promoter assay using 3TP-lux reporter showed that 227/236 double mutation significantly increased both basal and TGF- β-induced luciferase activity as compared to wild type in DR-26, TGF- β receptor-II-defective mink lung epithelial cells. Stable expression of 227/236 mutant enhanced migration and invasion as well as cell growth of HSC-2 cells, human oral squamous cancer cell line whose TGF- β signaling is not growth inhibitory. In 227/236 mutant transfectant, E-cadherin expression is reduced whereas snail expression has not been changed significantly. In orthotopic xenograft model to monitor the tumor growth, 227/236 mutant transfectant formed significantly larger tumors as compared to wild type transfectant. But, unexpectedly, there was no difference in the expression pattern of involucrin and E-cadherin in these tumor tissues, suggesting that this mutation did not affect EMT in vivo model system. In the study we present a novel gain-of-function mutation of TGF- β receptor II, which increased TGF- β signaling and thereby induced tumor growth without affecting EMT in HSC-2 oral squamous cancer cells. This work was supported by a grant from the Korea Research Foundation Grant funded by the Korean Government (MOEHRD, Basic research promotion fund KRF-2005-005-J05901). Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 1494.

In vivo study of fidelity of DNA double-strand break repair in bacteriophage T4

A method for in vivo studying the fidelity of DNA double-strand break (DSB) repair in bacteriophage T4 has been developed. The frequency of reversion of rII mutations to the wild phenotype was measured in i segC+ x i ets 1 segCDelta crosses, where ets 1 is an insertion in the initial part of the rII gene carrying a sequence recognized by SegC endonuclease; i designates a rIIB or rIIA mutation located at some distance from ets 1, and segCDelta is a deletion in the segC gene. In such cross, a DSB occurs in the site of ets 1. Their repair involves genetic recombination and DNA replication in the neighborhood of ets 1. In parallel, the frequency of reversion of the same i mutant in the absence of DSBs is measured in i x i self-crosses. Reversions of different types (base substitutions, deletions, insertions) can be studied with the use of structurally different i mutations located at varying distances from ets 1. The reversion frequencies were determined for three rIIB mutations and one rIIA mutation. The results obtained suggest that DSB repair in bacteriophage T4 is a process of high fidelity with the rate of errors that does not essentially exceed that in the case of usual phage multiplication.

Seymour Benzer 1921–2007

Seymour Benzer 1921–2007

Genomic profiles of colorectal cancers differ based on patient smoking status

Human sporadic colorectal cancer is the result of a lengthy somatic evolutionary process facilitated by various forms of genomic instability. Such instability arises endogenously from mutations in genes whose role is to preserve genomic integrity, and exogenously from environmental agents that generate genomic damage. We have found that cigarette smoking shifts the genomic profiles and genomic instability patterns of colorectal carcinomas. The genomic profiles of 57 consecutive cancers were examined; 31 cases were current or former smokers and 26 were nonsmokers. Genome-wide allelotypes of 348 markers were examined, along with comparative genomic hybridization (CGH) on ordered BAC microarrays, microsatellite instability, and inter-(simple sequence repeat) polymerase chain reaction instability. Tumors from nonsmokers exhibited losses of heterozygosity, particularly on chromosomes 14 and 18, whereas tumors from smokers exhibited a more diffuse pattern of allelic losses. Tumors from smokers exhibited higher overall rates of loss of heterozygosity, but showed lower rates of background microsatellite instability (MSI-L). On BAC array CGH, higher levels of generalized amplifications and deletions were observed in tumors from smokers, differentially affecting male smokers. In the transforming growth factor-β signaling pathway, MADH4 mutations were more common in tumors from smokers, whereas transforming growth factor-β RII mutations were more common among nonsmokers.

Evaluation of screening strategy for detecting hereditary nonpolyposis colorectal carcinoma

The Amsterdam criteria are used worldwide for the clinical diagnosis of hereditary nonpolyposis colorectal carcinoma (HNPCC). In Japan, clinical criteria (JCC) have been proposed to identify as many HNPCC cases as possible, but the suitability of the JCC remains uncertain. In this article, the authors evaluate retrospectively whether the JCC are adequate to diagnose HNPCC compared with the Bethesda guidelines (BG) and also investigated useful screening methods for HNPCC. The authors studied 452 colorectal carcinoma cases, of which 69 cases fulfilled the JCC (A, 12; B, 57) and 106 fulfilled the BG. Microsatellite instability (MSI) was examined for 452 cases. TGF beta RII, immunohistochemical staining, and germline mutations of hMLH1 and hMSH2 were analyzed in high-frequency MSI cases. High-frequency MSI was found in 21.7% (98 of 452). Germline mutations were detected in eight cases (hMLH1, three, hMSH2; five). Six cases fulfilled the JCC (A, four; B, two), and six fulfilled the BG. The germline mutation rate was significantly higher in the JCCA than in non-JCCA cases (33.3% vs. 0.91%; P < 0.001) and in cases with an age at onset younger than 50 years than older than 50 years (9.3% vs. 0.27%, P < 0.001). All germline mutation carriers had the TGF beta RII mutation. Immunohistochemically, a decreased nuclear staining was found in 57.3% (47 of 82) for hMLH1 and in 18.3% (15 of 82) for hMSH2. The frequency of predicted germline mutations was higher in cases with decreased hMSH2 than hMLH1 (33.3% vs. 6.4%; P = 0.016). The JCCA are suitable for selecting cases to analyze for gene mutations, but the JCCB are not useful for the clinical setting. The authors suggest that an age at onset younger than 50 years is also important for screening. Analyzing TGF beta RII mutations and immunohistochemical staining of hMLH1 or hMSH2 for cases with MSI phenotype are useful for selecting cases who should be tested for germline mutations.

Genetic evidence for the multi-step progression of mixed glandular-neuroendocrine gastric carcinomas.

A mixed glandular-neuroendocrine gastric carcinoma shows discrete, juxtaposed areas of adenocarcinoma and neuroendocrine carcinoma. In order to gain insight into the genetic events and clonality associated with the dual differentiation of a mixed gastric carcinoma, eight cases (two true composite and six neuroendocrine-dominant carcinomas) were examined by analyzing the genome-wide loss of heterozygosity (LOH). Of the eight mixed gastric carcinomas, one true composite and five neuroendocrine-dominant carcinomas showed a primary LOH that was shared by both the glandular and neuroendocrine components and a secondary LOH or mutations that were restricted to the neuroendocrine components. The glandular components contained mixed cell populations with or without primary LOH events, suggesting that a primary LOH arose during adenocarcinoma progression and that the LOH-positive cell served as a precursor for a neuroendocrine carcinoma. The neuroendocrine components were of a homogeneous population with various genetic alterations such as a LOH, p53 mutations, and microsatellite instability-associated transforming growth factor (TGF)-beta RII mutation. Therefore, most (six of eight cases) mixed glandular-neuroendocrine gastric carcinomas were likely to have sequentially evolved from a glandular precursor to a genetically heterogeneous adenocarcinoma and then to neuroendocrine differentiation. Two components of the other true composite carcinomas were shown to have reciprocally lost different alleles of identical loci on multiple chromosomes, suggesting that, occasionally (one of eight cases), dual differentiation concurrently arises from a single precursor, possibly as a result of non-disjunctional cell division.

Detection of TGF-beta type II receptor hot-spot mutations: the BAT-RII assay.

AbstractThe transforming growth factor-β (TGF-β) pathway is important in the growth control of many different cell types, particularly epithelial cells, and is often disrupted in the development of cancer (1,2). The most common mutation in the TGF-β pathway detected thus far is mutation of the type II receptor (RII) in colon cancers, particularly in tumors with defective mismatch repair or microsatellite instability (MSI) (3–5). These RII mutations occur in a repetitive region of coding sequence, a stretch of 10 adenines, and occur in greater than 90% of colon tumors with MSI (5). Frameshift mutations, with insertion or deletion of one or two adenines, result in premature termination of the receptor protein, with loss of the membrane anchor and intracellular kinase domain. This RII mutation also occurs in gastric and endometrial tumors (4) and may be a hot spot in other tumor types with microsatellite instability as well.KeywordsMicrosatellite InstabilityRoche Molecular BiochemicalArtifact BandPolyacrylamide SolutionIntracellular Kinase DomainThese keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Reduced expression of cyclooxygenase 2 proteins in hereditary nonpolyposis colorectal cancers relative to sporadic cancers

Background & Aims: Cyclooxygenase (COX) enzymes catalyze the conversion of arachidonic acid to prostaglandins. Evidence suggests that nonsteroidal anti-inflammatory drugs reduce the risk of colorectal cancer (CRC) and that this effect is mediated through COX inhibition. We analyzed and compared expression of the inducible COX-2 isoform in colorectal neoplasms from patients with hereditary nonpolyposis colorectal cancer (HNPCC), familial adenomatous polyposis (FAP), and sporadic CRC. Given that COX-2 is induced by transforming growth factor (TGF)-β and that TGF-β type II receptor (RII) mutations are found in HNPCCs, we determined the relationship between RII status and COX-2 expression. Methods: COX-2 protein expression was determined in colorectal epithelia using immunohistochemistry and Western blotting. Patients with HNPCC had known mutations in hMLH1 or hMSH2 genes and/or met the Amsterdam criteria. In CRCs from HNPCC cases, mutations were sought in the coding region of the RII gene using the polymerase chain reaction. Results: COX-2 was detected in adenomas from 2 of 3 HNPCC, 6 of 7 FAP, and 5 of 8 sporadic cases. In CRCs, COX-2 staining was found in 16 of 24 (67 %) HNPCC vs. 24 of 26 (92%) sporadic cases (P = 0.035) and in 2 of 2 FAP cases. Staining intensity was reduced in HNPCCs compared with sporadic CRCs (P = 0.035). Staining localized to the cytoplasm of neoplastic cells; normal epithelial cells were negative for COX-2. Overexpression of COX-2 in CRCs relative to normal mucosa was confirmed by Western blotting. TGF-β RII mutations were detected in 12 of 14 HNPCCs examined, including 3 of 4 COX-2–negative and 9 of 10 COX-2–positive cancers. Conclusions: The frequency and intensity of COX-2 expression was significantly reduced in HNPCCs relative to sporadic CRCs, and was not a consequence of RII mutations. Given that many HNPCCs express COX-2, inhibition of this enzyme may be an important strategy to prevent CRC in these patients.

Reply

The results of our study suggest that inactivation of the TGF-β signaling pathway is a common and important event in colon cancer pathogenesis and that mutation of TGF-βRII is the responsible mechanism in one third of all colon cancer cases. The mechanism causing TGF-β resistance in the remaining cases is still unknown and is an important area for active investigation. Mutations in the Smad family members, hSmad2, 3, and 4, may explain a portion of the additional TGF-β–resistant tumors; however, the low incidence thus far detected of hSmad 2, 3, and 4 mutations in human colon cancer implies hSmad mutations alone will not account for all the remaining cases. The results of our study raise the question of what pathophysiological advantage accrues to tumors from inactivating the TGF-β signaling pathway. Work from our group has shown RII mutations develop late in the adenoma to carcinoma sequence concurrent with the acquisition of malignant behavior of the tumor (Cancer Res 1998;58:3101-3104). This observation suggests TGF-βRII mutations promote cancer formation through mechanisms beyond release from TGF-β–induced growth inhibition, perhaps by promoting neoangiogenesis and/or tumor invasiveness. Strikingly, colon cancers often produce significant amounts of TGF-β. In an informative breast cancer model, Yin et al. recently reported that the cancer, although resistant to TGF-β growth inhibition, preserved autocrine TGF-β–mediated induction of PTHrp expression that favored the formation of bony metastatic disease (J Clin Invest 1999;103:197-205). In contrast, we find that colon cancers that are resistant to TGF-β–mediated growth inhibition have also lost TGF-β–induced transcriptional responses. Nonetheless, secreted TGF-β could contribute to the pathogenesis of TGF-β–resistant colon cancer via paracrine effects on neighboring stromal cells that could alter extracellular matrix, induce the growth of new blood vessels, and suppress the local activity of immune cells in the tumor environment. If such a model ultimately is verified, it would paradoxically imply a potential role for TGF-β antagonists as therapeutic agents in the treatment of TGF-β–resistant colon cancer. More directly, the discovery of RII mutations in a substantial portion of MSS as well as MSI colon cancers suggests the opportunity for novel therapeutic interventions such as gene reconstitution with TGF-βRII or the development of pharmaceutical agents that could reactivate postreceptor TGF-β signaling elements in these cancers. Unpublished observations in our laboratory suggest that gene reconstitution strategies may prove most successful in MSS colon cancer, because the MSI tumors rapidly mutate the reconstituted wild-type RII tumor-suppressor gene. Currently, we have developed a mutation-resistant version of wild-type RII and are evaluating its effectiveness as a tumor-suppressor of MSI colon cancer. The design of pharmaceutical agents that could reactivate postreceptor TGF-β signaling will become a potential reality as progress continues to be made in elucidating the gene targets that mediate TGF-β–induced growth inhibition and the mechanisms causing TGF-β resistance in colon cancers in which receptors are still wild-type. In addition to potential new treatment approaches, diagnostic assays that exploit the presence of mutations on RII could be developed. The mutant RII found in MSI colon cancer results from a frameshift mutation in the RII gene that prematurely truncates the protein, resulting in loss of the intracytoplasmic and transmembrane component of the receptor. Consequently, the mutant protein is predicted to be secreted by the tumor cells and should be detectable in the blood. Thus, the identification of RII mutations in colon cancer has not only provided insight into the mechanisms that contribute to the pathogenesis of colon cancer but also offers the promise of new therapeutic and diagnostic strategies to help treat this common malignancy.

The TGF-beta type II receptor in chronic myeloid leukemia: analysis of microsatellite regions and gene expression.

Genomic instability is one mechanism proposed to play a role in the disease progression of chronic myeloid leukemia (CML). Microsatellite regions in the type II transforming growth factor-beta receptor (TGF-beta RII) gene appear to be targets for mutation in some cancers displaying microsatellite instability (replication error phenotype, RER+). Furthermore, TGF-beta RII mutations in RER+ tumors have been associated with decreased TGF-beta RII mRNA levels. As TGF-beta is a potent negative growth regulator of hematopoietic cells, investigations were undertaken to determine whether inactivation of the receptor by microsatellite alteration might be involved in the progression of CML. Analysis of TGF-beta RII mRNA expression by RNase protection, with comparison of cells from the chronic, accelerated and blast phases of CML, showed no change in TGF-beta RII transcript levels during disease progression. However, during each phase of the disease, low levels of TGF-beta RII were detected when compared with the hematopoietic cells of normal donors. Furthermore, this decreased expression was also observed in the other myeloproliferative disorders, polycythemia rubra vera (PRV) and essential thrombocythemia (ET). The leukemia cell lines K562 and HL-60 had no detectable TGF-beta RII mRNA. Two microsatellite regions found altered in RER+ colon cancers were analyzed to establish if these sequences were aberrant in CML. No alteration was detected in either of these regions in any phase of the disease. These results suggest that alterations of the microsatellite regions in the TGF-beta RII gene are not involved in the progression of CML. Decreased expression of TGF-beta RII in CML cells and leukemia cell lines raises the possibility that altered expression of the receptor may play a role in the initiation and/or maintenance of the disease state.

Does mutation of transforming growth factor-beta type II receptor gene play an important role in colorectal polyps?

Mutations in the transforming growth factor-beta type II receptor (RII) gene that remain uncorrected due to mutation and inactivation of mismatch repair genes play an important role in hereditary nonpolyposis colorectal cancer (HNPCC) and in a subset of sporadic colorectal cancers. Some colorectal cancers develop from colorectal polyps. To elucidate the role of the RII gene in the generation of colorectal polyps, we analyzed 137 colorectal polyps from 100 patients for RII mutations and microsatellite instability (MSI). MSI was detected in three of 36 polyps from 25 patients. For one of these three polyps, the mobilities of the PCR products between polyp and nonpolyp tissues was different for only one microsatellite marker, and for the other two polyps the mobilities were different for more than two markers. These two polyps were obtained from one patient with ascending colon carcinoma and suspected HNPCC based on his clinical profile and family history. An RII mutation was detected in only one of these two polyps. RII may play a minor role in sporadic colorectal polyps. RII gene analysis in colorectal polyps may be a useful screening measure for potential HNPCC patients.

Mutation of the transforming growth factor-beta type II receptor gene in right-sided colorectal cancer: relationship to clinicopathological features and genetic alterations.

The presence of inactivating mutations in the transforming growth factor-beta (TGF-beta) type II receptor (RII) gene in the colon cancer suggests that it may behave like a tumour suppressor gene. RII is mutated in the majority of colon tumours exhibiting widespread microsatellite instability, a characteristic generally referred to as the replication error phenotype (RER+). We investigated the association between RII mutations and various clinicopathological variables and genetic alterations in a large series of sporadic adenocarcinomas arising in the proximal colon. RII mutations were found in 17 per cent (36/210) of right-sided tumours and in 86 per cent (32/37) of those displaying RER+. They were associated with the absence of lymph node invasion (P = 0.04), poor histological differentiation (P = 0.006), and with a trend for improved patient survival. Tumours with an RII mutation also showed non-significant trends for a lower incidence of p53 protein overexpression and of p53, K-ras, and APC gene mutation compared with tumours with normal RII. These results indicate that right-sided colorectal tumours containing RII mutations resemble those with the RER+ phenotype in terms of their clinicopathological features and genetic alterations.

Mutation of the transforming growth factor‐β type II receptor gene in right‐sided colorectal cancer: relationship to clinicopathological features and genetic alterations

The presence of inactivating mutations in the transforming growth factor-β (TGF-β) type II receptor (RII) gene in colon cancer suggests that it may behave like a tumour suppressor gene. RII is mutated in the majority of colon tumours exhibiting widespread microsatellite instability, a characteristic generally referred to as the replication error phenotype (RER+). We investigated the association between RII mutations and various clinicopathological variables and genetic alterations in a large series of sporadic adenocarcinomas arising in the proximal colon. RII mutations were found in 17 per cent (36/210) of right-sided tumours and in 86 per cent (32/37) of those displaying RER+. They were associated with the absence of lymph node invasion (P=0·04), poor histological differentiation (P=0·006), and with a trend for improved patient survival. Tumours with an RII mutation also showed non-significant trends for a lower incidence of p53 protein overexpression and of p53, K-ras, and APC gene mutation compared with tumours with normal RII. These results indicate that right-sided colorectal tumours containing RII mutations resemble those with the RER+ phenotype in terms of their clinicopathological features and genetic alterations. © 1998 John Wiley & Sons, Ltd.

Absence of mutations in the analysis of coding sequences of the entire transforming growth factor-beta type II receptor gene in sporadic human breast cancers.

The transforming growth factor-beta (TGFbeta) binds the type II TGFbeta growth factor receptor (TGFbetaRII) to inhibit the growth of most epithelial tissues. Most human colon and gastric cancers with microsatellite instability (MI) have frameshift mutations in polynucleotide repeats within the TGFbetaRII coding region; these mutations truncate the receptor protein and disable the serine/threonine kinase to produce TGF-beta resistance. To further investigate the type, frequency and tissue distribution of TGFbetaRII gene mutations, in this study, we examined 36 sporadic breast cancers. We previously produced eight intron based primer pairs for mutational analysis of the entire coding region of the TGFbetaRII gene. Using these primers, we developed protocols for polymerase chain reaction-single strand conformational polymorphism (PCR-SSCP) analysis of PCR products from genomic DNA samples of 36 breast cancer patients and we tested them for microsatellite instability (MI) at eight microsatellite loci. One case demonstrated MI (2.8%) and we found no mutations. These and other recent data indicate that TGFbetaRII mutations are essentially confined to colon and gastric cancers with MI. The narrow spectrum of tissues containing RII mutations illustrates the complexity of genetic checkpoints in human carcinogenesis.

Signal transduction by transforming growth factor-β: A cooperative paradigm with extensive negative regulation

Transforming growth factor-beta (TGF-beta) represents an evolutionarily conserved family of secreted factors that mobilize a complex signaling network to control cell fate by regulating proliferation, differentiation, motility, adhesion, and apoptosis. TGF-beta promotes the assembly of a cell surface receptor complex composed of type I (T beta RI) and type II (T beta RII) receptor serine/threonine kinases. In response to TGF-beta binding, T beta RII recruits and activates T beta RI through phosphorylation of the regulatory GS-domain. Activated T beta RI then initiates cytoplasmic signaling pathways to produce cellular responses. SMAD proteins together constitute a unique signaling pathway with key roles in signal transduction by TGF-beta and related factors. Pathway-restricted SMADs are phosphorylated and activated by type I receptors in response to stimulation by ligand. Once activated, pathway-restricted SMADs oligomerize with the common-mediator Smad4 and subsequently translocate to the nucleus. Genetic analysis in Drosophila melanogaster and Caenorhabditis elegans, as well as T beta RII and SMAD mutations in human tumors, emphasizes their importance in TGF-beta signaling. Mount ng evidence indicates that SMADs cooperate with ubiquitous cytoplasmic signaling cascades and nuclear factors to produce the full spectrum of TGF-beta responses. Operating independently, these ubiquitous elements may influence the nature of cellular responses to TGF-beta. Additionally, a variety of regulatory schemes contribute temporal and/or spatial restriction to TGF-beta responses. This report reviews our current understanding of TGF-beta signal transduction and considers the importance of a cooperative signaling paradigm to TGF-beta-mediated biological responses.

Mutation analysis of the transforming growth factor-beta type II receptor in human cell lines resistant to growth inhibition by transforming growth factor-beta.

The transforming growth factor-beta (TGF-beta) binds the type II TGF-beta growth factor receptor (RII) to inhibit the growth of most epithelial tissues. Most human colon and gastric cancers with microsatellite instability (MI) have frameshift mutations in polynucleotide repeats within the RII coding region; these mutations truncate the receptor protein and disable the serine/threonine kinase to produce TGF-beta resistance. To further investigate the type, frequency and tissue distribution of RII mutations, we selected 24 human cancer cell lines from various tissues which were previously reported to be resistant to the inhibitory effects of TGF-beta. We developed protocols for non-isotopic SSCP analysis of PCR products from genomic DNA samples, and we tested them for microsatellite instability. PCR-SSCP analysis followed by DNA sequencing identified deletion mutations in the exon 3 poly-adenine tract in three colon tumor cell lines: LS174T and SW48 had a single base deletion and LS411 had a two base deletion. Among the 24 previously unreported cell lines, only these three demonstrated microsatellite instability. These and other recent data indicate that RII mutations are essentially confined to colon and gastric cancers with microsatellite instability. The narrow spectrum of tissues containing RII mutations illustrates the complexity of genetic checkpoints in human carcinogenesis.

Absence of mutations in the transforming growth factor-beta type II receptor in sporadic lung cancers with microsatellite instability and rare H-ras1 alleles.

The transforming growth factor-beta type II receptor (RII) is commonly mutated in colon and gastric cancers with microsatellite instability (MI). We utilized our series of lung cancers with MI and rare alleles of the H-ras1 gene to determine the association between MI and RII mutations and searched the entire RII coding region in 33 lung cancers with MI by polymerase chain reaction-single-strand conformation polymorphism analysis. We found no mutations, and these data support other recent evidence that RII mutations rarely occur except in colon and gastric tumors with MI.